Clinical Trial Update: Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the combination of pembrolizumab, capecitabine, and bevacizumab for microsatellite-stable, mismatch repair proficient colorectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• KEYTRUDA (PEMBROLIZUMAB)
• Xeloda (capecitabine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Microsatellite Stable, Mismatch Repair Protein Proficient | Phase 2 | Status: COMPLETED | Results posted: 2025-02-28